KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Twist Bioscience (TWST) Equity Average (2018 - 2025)

Twist Bioscience (TWST) has disclosed Equity Average for 6 consecutive years, with $680.7 million as the latest value for Q2 2023.

  • On a quarterly basis, Equity Average fell 19.15% to $680.7 million in Q2 2023 year-over-year; TTM through Jun 2023 was $680.7 million, a 19.15% decrease, with the full-year FY2022 number at $685.1 million, up 49.41% from a year prior.
  • Equity Average was $680.7 million for Q2 2023 at Twist Bioscience, down from $725.1 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $842.0 million in Q2 2022 to a low of $127.0 million in Q1 2019.
  • A 5-year average of $493.7 million and a median of $599.6 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: skyrocketed 506.14% in 2019, then decreased 19.15% in 2023.
  • Twist Bioscience's Equity Average stood at $127.6 million in 2019, then soared by 281.8% to $487.1 million in 2020, then grew by 23.89% to $603.5 million in 2021, then increased by 27.23% to $767.9 million in 2022, then dropped by 11.35% to $680.7 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Equity Average are $680.7 million (Q2 2023), $725.1 million (Q1 2023), and $767.9 million (Q4 2022).